Skip to content

AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections

Professor Stefan Zeuzem speaking at the International Liver Congress 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Interferon-free BMS combo cures 90% of genotype 1 hepatitis C

Trevor Hawkins, from the Southwest CARE Center in New Mexico, presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Merck combination suppresses HCV in mono-infected and co-infected patients

Daclatasvir plus simeprevir are effective against hepatitis C genotype 1b

Christophe Hézode, from Hôpital Henri Mondor in Paris, presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Sofosbuvir & ribavirin cures 75% of genotype 1 HIV/HCV co-infected patients

Susanna Naggie from Duke Clinical Research Institute presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

AbbVie '3D' combination cures 99% of genotype 1b hepatitis C

Prof. Rajendar Reddy, of the University of Pennsylvania Hospital, presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Simeprevir cures almost 80% of first-time co-infected hepatitis C patients

Prof. Douglas Dieterich of Mount Sinai School of Medicine discusses recent advances in treatment of hepatitis C and HIV co-infection at CROI 2014. Photo by Liz Highleyman / hivandhepatitis.com

Faldaprevir plus interferon and ribavirin cures hepatitis C in most people with HIV/HCV co-infection

Douglas Dieterich, presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Six-week oral treatment can cure hard-to-treat hepatitis C patients

Anita Kohli, presenting at CROI 2014. Photo by Liz Highleyman, hivandhepatitis.com.